Should You Buy OHB Pediatrics Before the SPAC Merger Closes?
OHB Pediatrics Ltd. d/b/a Oak Hill Bio is going public through a merger with Research Alliance Corp III, the SPAC trading as RACC, with closing expected by year-end 2026. The setup is attractive if you want a Phase 3 rare-disease biotech with committed financing, but shareholders should watch dilution, clinical risk, and whether the market gives credit to a single-asset story.
OHB Pediatrics Ltd. d/b/a Oak Hill Bio is going public through a merger with Research Alliance Corp III, the SPAC trading as RACC, with closing expected by year-end 2026. The setup is attractive if you want a Phase 3 rare-disease biotech with committed financing, but shareholders should watch dilution, clinical risk, and whether the market gives credit to a single-asset story.
Deal at a Glance
SPAC partner: Research Alliance Corp III
SPAC ticker (trades now): RACC
Expected post-merger ticker: OAKH
Implied valuation: $193M EV
Expected close: Q4 2026
Est. first trading date: late 2026
Deal status: Announced
Source filing: SEC 425 (2026-07-28)
Company Overview
OHB Pediatrics Ltd. d/b/a Oak Hill Bio is a clinical-stage rare disease biotechnology company focused on rugonersen, an antisense oligonucleotide therapy for Angelman syndrome. It says rugonersen is its sole product candidate, and the company was formed in late 2024 as a wholly owned subsidiary of OHB Parent before commencing operations in 2025 after licensing the asset from Roche in February 2025. The company is incorporated in England and Wales.
The lead program is already in a pivotal Phase 3 BEACON trial, which dosed its first patient in July 2026. Oak Hill Bio says Angelman syndrome affects about 30,000 diagnosed patients in the U.S. and EU5 and that there are no approved disease-modifying therapies. That makes this a focused, high-risk biotech story: the upside depends almost entirely on one clinical asset, but the addressable market is meaningful for a rare-disease program.
The SPAC Deal
Research Alliance Corp III, which trades today under RACC, is combining with Oak Hill Bio at a $160 million pre-money equity value. The investor presentation also shows a $193 million enterprise value, based on $353 million equity value less $160 million of pro forma cash. Importantly, that $160 million figure is Oak Hill Bio’s fully diluted equity value and includes Roche’s equity interest tied to the licensing deal.
The SPAC has $75 million in trust, and the deal materials say any redemptions from trust will be backstopped dollar-for-dollar by sponsor RA Capital. That is a meaningful cushion versus a standard SPAC, although dilution still matters: the sponsor holds 1.324 million founder shares, 275,000 private placement shares, 4.500 million shares that convert at closing, and the PIPE adds 5.500 million shares. The financing package also includes a $45 million SAFE from RA Capital and a $55 million oversubscribed PIPE at $10.00 per share, for approximately $175 million in gross proceeds before expenses. The combined company is expected to list on Nasdaq Capital Market under OAKH, with closing expected by year-end 2026 and the first trading window likely in late 2026 if approvals and closing conditions are met.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The main use of proceeds is to fund the Phase 3 path for rugonersen and support the company through a potential NDA submission. The press release says the transaction, together with the recent $32.5 million Series A, is expected to provide runway through Phase 3 readout and potential NDA submission in 2H 2029, although that is a projection rather than a historical fact.
The SPAC route gives Oak Hill Bio speed and a financing package that is already largely committed. It also lets the company market a forward clinical and regulatory roadmap to public investors sooner than a traditional IPO might allow. For a pre-revenue biotech with a single lead asset, the sponsor backstop and PIPE are the key reasons this structure works: it reduces execution risk around the cash raise even if some SPAC holders redeem.
Financial Highlights
Oak Hill Bio is pre-revenue, so there are no commercial sales to anchor the story yet. The S-4 says net losses were $0.4 million in 2024, $15.6 million in 2025, and $13.5 million for the six months ended June 30, 2026. That pattern is typical for a clinical-stage biotech, where spending rises as the program moves into later-stage development.
Cash runway is tied to clinical progress and the financing package. The company’s disclosed runway is not a permanent cushion; the S-4 says it may need additional capital sooner if development costs rise or if it pursues additional programs. The company’s own projection is that the current financing, plus the Series A, should carry it through Phase 3 readout and potential NDA submission in 2H 2029, but shareholders should treat that as a plan, not a guarantee.
Risk Factors
The biggest risk is clinical: rugonersen is still in Phase 3, and success is uncertain. Oak Hill Bio is also a single-asset company, so any setback in BEACON would hit the entire equity story. Competition is real too, with Ultragenyx and Ionis already running Phase 3 programs in Angelman syndrome.
De-SPAC mechanics add another layer. Trust redemptions can drain cash from the deal, even though RA Capital has said it will backstop redemptions dollar-for-dollar. The PIPE and sponsor capital reduce that risk, but dilution remains meaningful from founder shares, private placement shares, the sponsor’s conversion economics, the SAFE, and the PIPE shares. The company may also need more financing later, and the merger can still slip if shareholder or regulatory approvals take longer than expected.
Comparable Public Companies
The clearest direct public comps are Ultragenyx Pharmaceutical (RARE) and Ionis Pharmaceuticals (IONS), both cited in the filing context as competitors in Angelman syndrome. Those names matter because they frame the competitive bar for rugonersen and show that Oak Hill Bio is entering a field where larger, better-capitalized biotech companies are already active.
Broader rare-disease and ASO comparables can include Biogen (BIIB) and PTC Therapeutics (PTCT), though they are not direct Angelman-specific peers. The filing set does not provide a formal trading multiple table, so there is no disclosed deal-deck comp range to quote. In general, the market has been rewarding late-stage rare-disease assets with cleaner data and punishing single-asset programs when timelines slip, which makes the Phase 3 readout path the key valuation driver here.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
This is a straightforward de-SPAC biotech bet: a Phase 3 rare-disease asset, a Roche-originated program, and a financing structure that is better protected than many SPAC deals. The setup favors investors who are comfortable underwriting clinical risk and who want exposure to a potential 2029 regulatory catalyst rather than near-term revenue.
What shareholders should watch next is whether the merger stays on track to close by year-end 2026, whether redemptions stay manageable despite the sponsor backstop, and how the market reacts to the dilution stack once OAKH starts trading. The reason this matters now is that the company is moving from private clinical execution to public-market scrutiny, and the first trading window should arrive in late 2026 if the deal clears its remaining approvals.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.